ArticleResearch in heart yield and translational medicine2026
Agranulocytosis after High Cumulative Doses of Ceftriaxone in Infective Endocarditis: A Rare but Serious Adverse Reaction.
Article in Research in heart yield and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highlights: Ceftriaxone-induced agranulocytosis is rare but can occur after high cumulative doses (≥60 g) or prolonged therapy.Routine CBC monitoring is essential during long-term ceftriaxone treatment, especially in infective endocarditis.Prompt drug withdrawal, antibiotic switch, and rhG-CSF (filgrastim) administration lead to rapid neutrophil recovery.The Naranjo adverse drug reaction probability scale is a useful tool for causality assessment in antibiotic-induced agranulocytosis. Background: Agranulocytosis is a serious, life-threatening condition characterized by a severe reduction in the number of peripheral neutrophils (<0.5 × 10 Case Presentation: A 56-year-old man diagnosed with native valve infective endocarditis (Streptococcus mitis) was treated with 2 g/day of intravenous ceftriaxone. In the fifth week of treatment, after receiving a cumulative dose of 60 g, the patient developed severe agranulocytosis, reaching a neutrophil nadir of 0.1 × 10 Conclusion: Ceftriaxone induced agranulocytosis, albeit rare, is a potentially fatal complication of prolonged therapy. Regular complete blood count monitoring and prompt management-based on drug withdrawal, appropriate antimicrobial coverage, and rhG CSF administration-are essential for favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.